Skip to content
value.today

Pulmatrix, Inc.

PULM
$6 Mmarket cap on Aug 1, 2026-25.0% since Jan 2024
Compare
World rank
#26,621
Revenue
—
For year ending December-2025
Net income
$-5 M
SEC filing
Employees
—

Pulmatrix, Inc. in brief

Pulmatrix, Inc. is a listed company in the Biotechnology industry, based in Framingham, Massachusetts, USA. Its market value was $6 M on 1 August 2026, which makes it the 26,621st largest listed company in the world and the 4,372nd largest in the USA on this site. Its shares trade under the symbol PULM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Pulmatrix, Inc.

We are a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using our patented iSPERSE™ technology. Our proprietary product pipeline includes treatments for central nervous system disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease and allergic bronchopulmonary aspergillosis. Our product candidates are based on our proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.

From the company's annual report filed with the US SEC: read the report

Pulmatrix, Inc. timeline

4 events, 2013–2020
  1. 2013
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2015
  6. ✎
    Renamed Pulmatrix, Inc.
    Formerly Ruthigen, Inc..
  7. 2020
  8. 💰
    Record revenue of $13 million
    FY2020, the highest of the 7 years on record.

Events of Pulmatrix, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$11 M$22 M$33 M$44 M2020202120222023202420252026

World rank over time

▲ up 49 places since 2020
2020-01-01: #23497#23,49720202021-01-01: #21333#21,33320212022-01-07: #30371#30,37120222022-12-25: #30806#30,80620222024-01-05: #31638#31,63820242026-03-08: #12981#12,98120262026-08-01: #23448#23,4482026

Rank in USA: #4,314 (Jan 2020) · #4,154 (Jan 2021) · #5,334 (Jan 2022) · #5,472 (Dec 2022) · #4,557 (Jan 2024) · #2,417 (Mar 2026) · #4,099 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.6×
Free cash flow yield
-185.3%
Net margin
—
Operating margin
—
Return on equity
-135.4%
Liabilities / assets
8.0%
Net debt
$-1M
Revenue growth
+7.0%
R&D / revenue
91.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-21M$0MFY18Fiscal year ending Dec 2019: revenue $8M, net income $-21M$8MFY19Fiscal year ending Dec 2020: revenue $13M, net income $-19M$13MFY20Fiscal year ending Dec 2021: revenue $5M, net income $-20M$5MFY21Fiscal year ending Dec 2022: revenue $6M, net income $-19M$6MFY22Fiscal year ending Dec 2023: revenue $7M, net income $-14M$7MFY23Fiscal year ending Dec 2024: revenue $8M, net income $-10M$8MFY24Fiscal year ending Dec 2025: revenue —, net income $-5M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-5M$-5M—
Dec 2024$8M+7.0%$-10M$-10M-122.4%
Dec 2023$7M+20.3%$-15M$-14M-193.4%
Dec 2022$6M+17.4%$-19M$-19M-310.4%
Dec 2021$5M-59.1%$-20M$-20M-390.1%
Dec 2020$13M+59.7%$-10M$-19M-152.9%
Dec 2019$8M+5173.3%$-21M$-21M-260.4%
Dec 2018$0M—$-20M$-21M-13706.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M——$-1.41—
Dec 2024$-11M$0M$-11M$-2.62—
Dec 2023$-16M$1M$-17M$-3.87—
Dec 2022$-19M$0M$-19M$-5.46—
Dec 2021$-20M$0M$-20M$-8.63—
Dec 2020$-12M$0M$-13M$-13.43—
Dec 2019$3M$0M$3M$-1.23—
Dec 2018$-17M$0M$-17M$-4.98—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-3M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-2M$0MDec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue —, net income $-1M—Mar ’26Three months to Jun 2026: revenue —, net income $-1M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Pulmatrix, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-5 M
Net income
$-5 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$4 M
Total liabilities
$0 M
Total equity
$4 M

As of December-2025

Top 16 institutional investors in Pulmatrix, Inc.#

As of Sep 30, 2026
16 institutions held 361,404 shares (about 9.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 16 largest institutional investors in Pulmatrix, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Renaissance Technologies LLC120,220-2,478 (-2.02%)3.29%$0 MNov 12, 2026
2BlackRock, Inc.54,8990 (0.00%)1.50%$0 MNov 13, 2026
3Shay Capital LLC33,958+15,101 (+80.08%)0.93%$0 MNov 16, 2026
4Geode Capital Management, LLC33,202-97 (-0.29%)0.91%$0 MNov 6, 2026
5Vanguard Capital Management LLC32,2940 (0.00%)0.88%$0 MNov 13, 2026
6SBI Securities Co., Ltd.30,165-1,120 (-3.58%)0.83%$0 MOct 22, 2026
7Vanguard Fiduciary Trust Co14,7150 (0.00%)0.40%$0 MNov 13, 2026
8Susquehanna International Group, LLP14,252New0.39%$0 MNov 16, 2026
9State Street Corp13,9450 (0.00%)0.38%$0 MNov 12, 2026
10Virtu Financial LLC13,722New0.38%$0 MNov 17, 2026
11UBS Group AG10-505 (-98.06%)0.00%$0 MNov 10, 2026
12Royal Bank Of Canada70 (0.00%)0.00%$0 MNov 16, 2026
13Farther Finance Advisors, LLC70 (0.00%)0.00%$0 MOct 8, 2026
14Barclays PLC4-11 (-73.33%)0.00%$0 MNov 6, 2026
15Allworth Financial LP30 (0.00%)0.00%$0 MNov 17, 2026
16Northwestern Mutual Wealth Management Co10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Pulmatrix, Inc.#

5 funds hold shares worth $0 M (about 1.9% of the company). Since their previous reports 1 added shares and 1 sold.
Mutual funds holding Pulmatrix, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.32,294$0 M0.88%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC23,014$0 M0.63%<0.01%+18%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,228$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,570$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC4,427$0 M0.12%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Pulmatrix, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
Pulmatrix, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark T. IwickiDirectorBuy+307,000——307,000Form 4
filed ARCH Venture Partners VII, L.P.Former 10% ownerBuyindirect+1.15 M——3.44 MForm 4
filed Matthew L. ShermanDirectorBuy+20,000——20,000Form 4
filed Polaris Venture Management Co. V, L.L.C.10% ownerBuyindirect+345,551——1.56 MForm 4
filed Polaris Venture Management Co. V, L.L.C.10% ownerBuyindirect+6,478——29,178Form 4
filed Polaris Venture Management Co. V, L.L.C.10% ownerBuyindirect+769,989——3.47 MForm 4
filed Polaris Venture Management Co. V, L.L.C.10% ownerBuyindirect+15,007——67,729Form 4
filed Polaris Venture Management Co. V, L.L.C.10% ownerBuyindirect+5,275——23,875Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Pulmatrix, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
39,538
1.1% of shares · 1.32 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2.5 reverse split

Trading halts

  • 2026-03-26 11:59 UTC, code T3, resumed 12:30 UTC
  • 2025-12-19 14:30 UTC, code LUDP, resumed 14:35 UTC
  • 2025-06-25 15:11 UTC, code LUDP, resumed 15:16 UTC
  • 2025-06-23 16:15 UTC, code LUDP, resumed 16:20 UTC
  • 2025-06-23 16:08 UTC, code LUDP, resumed 16:13 UTC

Fails to deliver

  • : 276 shares at $1.66
  • : 18 shares at $1.72
  • : 844 shares at $1.88
  • : 87 shares at $1.70
  • : 1,576 shares at $1.63

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Pulmatrix, Inc. scorecard#

Passes 3 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.41 vs -2.62Diluted EPS -1.41 in fiscal 2025 against -2.62 the year before (report's currency).
    • ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$19 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-80.9%-80.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities12.5×Current ratio 12.52 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Pulmatrix, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Pulmatrix, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—7.87.36.15.2137.90.20.30.8
Research and development0.07.21618151613131010
General and administrative5.17.86.56.86.46.98.57.57.68.0
Operating expenses5.218222525222921r1826
Operating income−5.2−9.8−15−19−20−9.9−21−20r−17−25
Interest and finance income0.10.5———0.10.30.0——
Interest expense and finance costs———————0.20.60.9
Net interest income—0.50.90.30.00.1————
Other non-operating income (expense)0.00.20.60.1−0.0−9.40.1−0.2r−0.6r−0.0
Income before tax————————−18−31
Income tax0————————−3.0
Net income including minority interests——————−21−21−18—
Net income attributable to shareholders−5.2−9.6−14−19−20−19−21−21−18−28
Earnings per share, basic-1.41-2.62-3.87-5.46-8.63-13.43r-1.23-4.98-9.32r-1.88
Earnings per share, diluted-1.41-2.62-3.87-5.46-8.63-13.43r-1.23-4.98-9.32r-1.88
Shares, weighted average (basic)3.73.73.7r3,448r2.7—————
Shares, weighted average (diluted)3.73.73.7r3,4482.71.4r174.11.9r15
Balance sheet
Cash and cash equivalents4.19.519365432232.63.64.2
Receivables——0.91.30.10.17.2———
Other current assets0.00.40.71.10.90.7r0.80.70.70.6
Current assets4.19.921385532r313.34.24.8
Property, plant and equipment——1.20.20.30.40.30.40.60.8
Right-of-use (leased) assets——100.72.11.50.6———
Goodwill—————3.63.6111111
Total assets4.19.934415938r36151617
Accounts payable0.30.81.91.20.80.9r0.61.20.50.7
Debt due within a year———————03.22.6
Current liabilities0.30.93.95.04.48.2r172.95.8r4.7
Long-term debt—————————3.2
Lease liabilities (non-current)——8.3—0.90.6————
Total liabilities0.31.0169.81115r252.95.87.9
Retained earnings−302−297−288−273−255−234−215−195−174−156
Shareholders' equity3.88.9183147231112108.8
Total liabilities and equity4.19.934415938r36151617
Shares outstanding3.73.73.73.63.21.8r204.9r2.1r15
Cash-flow statement
Depreciation and amortization—0.10.10.20.20.20.20.20.20.3
Share-based compensation0.00.51.01.11.21.22.13.02.84.0
Cash from operating activities−5.4−11−16−19−20−123.2−17−14−13
Capital expenditure—−0.4−0.7−0.1−0.1−0.3−0.1−0.0−0.1−0.5
Cash from investing activities—−0.4−0.7−0.1−0.1−0.3−0.1−0.0−0.1−0.4
Debt issued—————0.6————
Debt repaid—————−0.6————
Shares issued——0.11.4377.3183.7——
Cash from financing activities——0.11.24321181614−1.0
Change in cash−5.4−11−17−18248.221−1.0−0.6−15
Report10-K/A10-K/A10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Pulmatrix, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Change in control 3 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 10

Pulmatrix, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Results announced8-K
Results announced8-K
Change in controlMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Agreement ended8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Acquisition or sale completed8-K
Change in controlMaterial agreement8-K
Shareholder vote8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Change in controlDirectors and officersMaterial agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 27, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Pulmatrix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$1 MPrivate placement after listingUnder $2 million1equitySEC
Apr 2020$8 MPrivate placement after listing$2 to $10 million3optionsSEC
Feb 2019$2 MPrivate placement after listing$2 to $10 million7optionsSEC
Dec 2018$4 MPrivate placement after listing$2 to $10 million1optionsSEC
Jun 2015$21 MPrivate placement after listing$10 to $50 million12equity, optionsSEC
Jun 2015$3 MPrivate placement after listing$2 to $10 million34equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Pulmatrix, Inc.#

1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $112 K a year.

Certified, FY2023
1
#2,039 among companies on value.today
Worker positions
1
Median wage offered
$112 K
a year, full-time
Applications filed
1
Pulmatrix, Inc.: most frequent H-1B job titles in fiscal 2023
Job titlePositionsMedian wage offered
Engineer I/Scientist IChemists1$112 K

Where: Lexington, MA 1

Pulmatrix, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202311$112 K1
FY202222$101 K2
FY202022$96 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Pulmatrix, Inc.

How Pulmatrix, Inc. compares in Biotechnology

  • Market cap$6 M · higher than 7% of 726
  • Revenue growth7.0% · higher than 50% of 438
  • Price / book1.6× · lower than 65% of 534
  • FCF yield-185.3% · higher than 2% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Pulmatrix, Inc.🇺🇸$6 M——+7.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Pulmatrix, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Pulmatrix, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Pulmatrix, Inc.? Suggest a correction